Sotera Health announced a secondary offering of 20 million shares by Warburg Pincus and GTCR affiliates.
Quiver AI Summary
Sotera Health Company announced a secondary offering of 20,000,000 shares of its common stock, exclusively offered by affiliates of Warburg Pincus LLC and GTCR LLC, with no shares being sold by the company itself. Sotera will not receive any proceeds from the offering, which covers the costs under its Registration Rights Agreement. Goldman Sachs & Co. LLC is acting as the underwriter for the offering, and the offering will be conducted solely through a prospectus. A registration statement for the offering was filed with the SEC in February 2024. This announcement does not constitute an offer to sell or solicit offers to buy these securities, and it includes forward-looking statements regarding risks and uncertainties related to the company’s operations. Sotera Health, which provides sterilization solutions and lab testing services, operates under three brands: Sterigenics, Nordion, and Nelson Labs.
Potential Positives
- The launch of a secondary offering of 20,000,000 shares signals a strong market interest and confidence in the company's stock despite not receiving proceeds from the offering.
- The involvement of reputable underwriter Goldman Sachs & Co. LLC enhances the credibility and perception of the offering in the financial market.
- The company maintains its focus on providing essential services, reaffirming its commitment to its mission of "Safeguarding Global Health," which may strengthen investor and customer trust.
- By clarifying that no shares are being sold by the company itself, it indicates that existing shareholders (Warburg Pincus and GTCR) are facilitating their exit while potentially benefiting the liquidity of the stock.
Potential Negatives
- The company is not benefiting financially from the secondary offering, as it will not receive any proceeds from the sale of shares.
- The offering being conducted entirely by affiliates of Warburg Pincus and GTCR may raise concerns about dilution of existing shareholder value without direct corporate involvement.
- The Company undertakes no obligation to update forward-looking statements, which may perpetuate uncertainty around future performance.
FAQ
What is the purpose of Sotera Health's secondary offering?
Sotera Health's secondary offering aims to sell 20,000,000 shares of its common stock by affiliates of Warburg Pincus and GTCR.
Who is selling the shares in the offering?
The shares are being sold by certain affiliates of Warburg Pincus LLC and GTCR LLC as selling stockholders.
Will Sotera Health receive proceeds from the offering?
No, Sotera Health will not receive any proceeds from the secondary offering.
How can I obtain a prospectus for the offering?
Copies of the preliminary prospectus can be obtained from Goldman Sachs & Co. LLC's Prospectus Department.
What is Sotera Health's mission?
Sotera Health's mission is "Safeguarding Global Health," providing sterilization solutions and lab testing services for the healthcare industry.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SHC Insider Trading Activity
$SHC insiders have traded $SHC stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SHC stock by insiders over the last 6 months:
- MICHAEL P RUTZ (President of Sterigenics) sold 126,611 shares for an estimated $2,074,305
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SHC Hedge Fund Activity
We have seen 149 institutional investors add shares of $SHC stock to their portfolio, and 107 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TPG GP A, LLC removed 6,786,110 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $75,461,543
- SCULPTOR CAPITAL LP added 2,462,489 shares (+27.2%) to their portfolio in Q2 2025, for an estimated $27,382,877
- ARROWMARK COLORADO HOLDINGS LLC removed 1,867,829 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $20,770,258
- POINT72 (DIFC) LTD added 1,136,326 shares (+192.6%) to their portfolio in Q2 2025, for an estimated $12,635,945
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 1,101,604 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,249,836
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,007,963 shares (+12.5%) to their portfolio in Q2 2025, for an estimated $11,208,548
- KHROM CAPITAL MANAGEMENT LLC added 988,801 shares (+174.1%) to their portfolio in Q2 2025, for an estimated $10,995,467
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SHC Analyst Ratings
Wall Street analysts have issued reports on $SHC in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 06/24/2025
- Goldman Sachs issued a "Buy" rating on 05/05/2025
To track analyst ratings and price targets for $SHC, check out Quiver Quantitative's $SHC forecast page.
$SHC Price Targets
Multiple analysts have issued price targets for $SHC recently. We have seen 3 analysts offer price targets for $SHC in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Luke Sergott from Barclays set a target price of $13.0 on 06/24/2025
- Matthew Sykes from Goldman Sachs set a target price of $17.0 on 05/05/2025
- Jason Bednar from Piper Sandler set a target price of $13.0 on 04/23/2025
Full Release
CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 20,000,000 shares of its common stock, par value $0.01 per share. All 20,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registration Rights Agreement.
Goldman Sachs & Co. LLC is acting as the underwriter for the Offering.
The Offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the Offering may be obtained, when available, from: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by email at [email protected].
A registration statement relating to these securities was filed with the Securities and Exchange Commission on February 27, 2024, and became effective automatically.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-looking Statements:
Statements in this press release regarding the Company that are not historical facts are “forward-looking statements” that involve risks and uncertainties. Certain of these risks and uncertainties are described in the Company’s registration statement on Form S-3 filed with the SEC, including under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements,” under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent Annual Report on Form 10-K. Forward-looking statements made in this release speak only as of the date of this release, and the Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances, except as required by law.
About Sotera Health:
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
INVESTOR RELATIONS CONTACTS:
Jason Peterson
Vice President, Investor Relations and Treasurer, Sotera Health
[email protected]
MEDIA CONTACT:
Kristin Gibbs
Chief Marketing Officer, Sotera Health
[email protected]
Source: Sotera Health Company
